Acromegaly and Gigantism- Epidemiology Forecast to 2023; New Report Launched

DrugPipeline.net has announced the addition of “Acromegaly and Gigantism- Epidemiology Forecast To 2023” research report to their website DrugPipeline.net


Bangalore, Karnataka -- (SBWIRE) -- 04/07/2017 -- "Acromegaly and Gigantism- Epidemiology Forecast to 2023" Report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk factors, disease burden with special emphasis.

Acromegaly is a rare but serious hormonal disorder caused by excessive growth hormone (GH) in the blood in adults. Acromegaly in adults occurs mainly in middle-aged men and women. In This condition, the bones increase in size, including those of the hands, feet and face. Acromegaly is uncommon and physical changes occur gradually thus the condition often isn't recognized immediately and if not treated promptly, it can lead to serious illness and even become life-threatening.

According to Publisher's estimates, the prevalent cases of Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.

Gigantism is excessive production of GH in children which is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results from high linear growth due to excessive action of insulin like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood. According to Publisher's estimates, prevalent cases of Gigantism in the 6 MM are expected to increase with a CAGR of 2% and Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Acromegaly and Gigantism.
Identifying prevalent patient populations as well as risk factors in the global Acromegaly and Gigantism market will help to improve product design, pricing, and launch plans.

Spanning over 51 pages "Acromegaly and Gigantism- Epidemiology Forecast To 2023" report covers Report Introduction, Acromegaly and Gigantism: Overview, Treatment, Appendix, Report Methodology

For more information Visit at: http://www.drugpipeline.net/delveinsight/acromegaly-and-gigantism-epidemiology-forecast-2023

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.